Home > Insider Trading > Filing (0001209191-13-057048)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1131324	Genomic Health Inc	GHDX	Services-Medical Laboratories (8071)	770552594

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1333482	J Kimberly Popovits	301 Penobscot Drive Redwood City CA 94403	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2013-12-03	350	$0.00	207,082	No	5	G	Indirect	Held by the Popovits 2010 Trust
Common Stock	Disposition	2013-12-03	400	$0.00	206,682	No	5	G	Indirect	Held by the Popovits 2010 Trust
Common Stock	Disposition	2013-12-03	400	$0.00	206,282	No	5	G	Indirect	Held by the Popovits 2010 Trust
Common Stock	Acquisiton	2013-12-12	2,500	$9.39	29,366	No	4	M	Direct
Common Stock	Disposition	2013-12-12	2,500	$30.68	26,866	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	5	G	Indirect	Held by the Popovits 2010 Trust
No	5	G	Indirect	Held by the Popovits 2010 Trust
No	5	G	Indirect	Held by the Popovits 2010 Trust
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2013-12-12	2,500	$0.00	2,500	$9.39

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
15,113		2015-12-01	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	12,298	Indirect	Held by UBS for Benefit of Kimberly Popovits
Common Stock	15,744	Indirect	Held in trust for the benefit of Ms. Popovits' son, of which Ms. Popovits is trustee.

Footnotes

These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on February 20, 2013.
Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
Represents weighted average sale price. Actual sale prices ranged from $30.16 to $30.98.
Includes 10,000 restricted stock units awarded February 5, 2012, of which 1/3 vest on each of February 15, 2014 and 2015 and the 1/3 of the shares that vested on February 15, 2013, net of withholding.
Includes 10,000 restricted stock units awarded January 27, 2011, of which 1/3 of the shares vest on February 15, 2014, and the 1/3 of the shares that vested on each of February 15, 2012 and 2013, net of withholding.
Includes 9,000 restricted stock units awarded July 25, 2013, of which 1/3 of the shares vest on each of February 15, 2014, 2015 and 2016.
The option became exercisable as to 25% of the shares on December 1, 2006, and became exercisable as to 1/48th of the shares each full month thereafter.